Good news! MAPS (Multidisciplinary Association for Psychedelic Studies), with assistance from the United States Government, have re-initiated study of the therapeutic potential of psychedelic experiences. As is noted in the article, many of these studies have already passed phase-one of the FDA testing, including studies of psilocybin and MDMA. Disorders such as chronic depression, anxiety, PTSD, or alcohol-related mental disorders have been considered for treatment. Alcohol-related research has had a successful focus in the field of Ibogaine treatment in other recent studies, as is noted by MAPS. Mescaline has yet to be introduced to the FDA for approval. DMT however, in large thanks to Dr. Strassman's studies, has been approved and has in some cases passed both phase-one & two of the approval process. Scientific American Mind brings to the public, a basic understanding of psychedelic science, a differentiation between classes of psychedelics, and perhaps most importantly, a perspective of legitimacy and legality. This article represents (hopefully) a major step in awareness of psychedelic science and its therapeutic effects as a facet of the greater consciousness and acceptance of man.